Current studies at East Sussex Healthcare NHS Trust.
Research at East Sussex Healthcare NHS Trust
is a clinical trial testing whether a new medicine called inclisiran prevents heart attacks and strokes.
Local Principal Investigator – Dr Andrew Marshall
HD Grid versus Circular mapping catheter for Assessment of Pulmonary Vein Reconnection
Summary – Comparative study of Advisor HD Grid versus Circular Mapping Catheters in assessment of pulmonary vein isolation following previous ablation for Atrial Fibrillation
Local Principal Investigator – Dr Rick Veasey
SIGNET will be the largest randomised controlled trial in organ donation. The trial will evaluate the benefits of Simvastatin given to organ donors on outcomes in organ recipients.
Summary – Statins in Organ Donor Management An evaluation of the benefits of a single dose of Simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients
Local Principal Investigator – Dr Sinan Bahlool
Address 2 this research project is learning about the characteristics of people newly diagnosed with type 1 with diabetes in the UK, and at the same time supporting other research into type 1 diabetes.
Targeting Immune Pathways
Summary – The immune system is a network of cells, tissues and organs that work together to defend the body against infection. Over 70% of the immune system is based in the gastrointestinal tract where it plays a major role in a complex interaction with trillions of microbes to maintain health. The breakdown of this interaction leads to diseases such as inflammatory bowel disease (IBD) and contributes to many others including colorectal cancer.
We work on the nature of intestinal immune responses in health including diseases such as IBD and in the inflammation associated with some gastrointestinal cancers. We have used modern single cell technologies to redefine the cells of the human intestine (3). These technologies allow us to build a map of rare intestinal tissue cells in health and disease. Using this approach, we have discovered novel non-uniformity between various cell types and have then compared how these new cell types change to drive disease. We’ve also defined transcription factors and surface markers that enable these cells to be knocked out for studies in model systems and defined key cellular changes demonstrating new avenues for therapeutic targeting in this disease.
Around 40% of patients fail to respond or adequately respond to available immunotherapies. In this work, we will build on our previous findings to explore how the immune system is imbalanced in chronic inflammation associated colorectal cancer. This study will create an atlas of rare human intestinal cells and will highlight pathways that drive inflammation in early disease compared to chronic unresponsive disease. Based on this information we will generate disease identifiers capable of indicating inflammation or responsiveness to particular therapies. In addition, we will generate novel drug targets for those with unresponsive IBD and colorectal cancer.
Local Principal Investigator – Judith Tidbury
ECHELON-3 Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Summary – A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL).
Local Principal Investigator – Dr Abier Elzein
Myeloma XIV (FiTNEss)
Summary – Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I).
Local Principal Investigator – Dr Nigel Sargant
UK MS Register – The MS Register is a ground-breaking study designed to increase our understanding of living with MS in the UK.
ADD-ASPIRIN is a large randomised clinical trial, which is taking place in the UK, Republic of Ireland and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths.
WHiTE 11- FRUITI
Summary – World Hip Trauma Evaluation – FRUITI: Fix or Replace Undisplaced Intracapsular fractures Trial of Interventions
Local Principal Investigator – Mr Oliver Keast-Butler
Summary – Dual mobility versus standard articulation total hip replacement in the treatment of older adults with a hip fracture.
Local Principal Investigator – Mr Christopher Buckle
Summary – The aim of this research programme is to find out whether an injection of a drug called adalimumab can reduce pain and improve function in people with frozen shoulder, if given during the early painful phase of frozen shoulder.
Local Principal Investigator – Vincent Gallagher
To develop a decision-making tool using a convolutional neural network that identifies abnormalities on brain MRI scans:
Local Principal Investigator – Dr David Sallomi